Background {#Sec1}
==========

Although a number of different poxvirus-based vaccine vectors are available \[[@CR1]--[@CR7]\], there is still a need for additional vaccine vectors as well as improvement of the vectors. The unique response elicited by the host to different vectors means that vectors can be selected or engineered according to a desired host response. Host-range restricted poxviruses have been shown to successfully activate the host immune system \[[@CR8], [@CR9]\] and evidence exists that each virus does this in a different way, with an accompanying different pattern of transcript abundance \[[@CR10]--[@CR15]\]. The poxviruses ALVAC (based on canarypox virus), modified vaccinia Ankara (MVA) and NYVAC (both based on vaccinia virus (VACV) and have specific deletions) produce distinct innate immune profiles, characterised by different induction of pro-inflammatory and antiviral cytokines and chemokines in both rhesus monkeys and human PBMC \[[@CR16]\].

It has been shown that in non-permissive cells, Fowlpox virus (FWPV) proceeds further into the poxvirus life cycle than Canarypox virus (CNPV) \[[@CR17]\]. Heterologous HIV gag/pol and env genes are more efficiently expressed by FWPV than CNPV in vitro due to longer transgene expression \[[@CR18]\]. However, the only successful HIV-1 vaccine clinical trial to date (31.2 % protection from HIV-1 infection) has been the Thai RV144 trial involving priming with ALVAC expressing HIV-1 gp120/Gag-Pro and boosting with a recombinant glycoprotein 120 subunit, AIDSVAX \[[@CR7]\]. Head to head comparisons of poxvirus-vectored vaccines would help to establish the differences between the different vaccine vectors and the vaccine-induced response to achieve protection against pathogens and cancers.

Innate immunity is critical for directing the adaptive immune response to antigen and influences the magnitude and quality of the long-lived, protective immune responses to pathogens or vaccines \[[@CR19]\]. Application of the systems biology approach to vaccine development ("systems vaccinology") and establishment of innate immune signatures has proven useful in predicting the immunogenicity of the highly effective yellow fever vaccine (YF-17D) \[[@CR20]\], seasonal influenza vaccines \[[@CR21]\] and the immunogenic but inefficacious Merck Adenovirus type 5 (Ad5) based HIV vaccine \[[@CR22]\]. A better understanding of the mechanisms underlying the optimal innate immune responses would aid rational vaccine development.

Type 1 interferons (IFNα/β) are expressed rapidly in response to viral infection, and, in turn activate many interferon stimulated genes (ISGs) which exert various antiviral effector functions. A fine balance of IFN is required for successful vaccination using a live virus vector. The vector should induce enough type I IFNs to activate the immune system, yet not enough to inhibit viral DNA replication and gene expression before antigen presentation can occur \[[@CR23]\]. This is corroborated by Johnson et al. (2012), who compared recombinant (r) Ad types 5, 28 and 35. Specific IFN-α induction by rAd28 and rAd35 significantly lowered the immunogenicity of these vectors compared to rAd5 which did not induce IFN-α expression \[[@CR24]\]. The effect of type 1 IFN responses on different vaccines requires delineation of innate immune signatures and how they determine subsequent adaptive responses.

Microarray analyses performed in vitro have been used to investigate the effects of VACV (\[[@CR12]\], MVA \[[@CR11]\] and NYVAC \[[@CR13]\] infection on HeLa cell gene expression. Gene expression profiles in human monocyte derived dendritic cells (MDDCs) have also been generated with MVA, NYVAC \[[@CR14]\] and ALVAC \[[@CR15]\]. Furthermore, a comparison of the closely related VACV-derived vectors NYVAC and MVA revealed significant differences in antigen production and host gene dysregulation in cell culture \[[@CR25]\]. Consequently we hypothesized that genetically diverse poxvirus strains would induce significant differences in host gene expression. The interaction of poxviruses with the host is not just dependent on the actual cell infected by the virus but also on the factors secreted by those infected cells and their effects on the surrounding cells. Although in vitro expression studies have provided useful information, gene expression profiles performed in cell culture may not accurately reflect the changes in the system that occurs as a result of infection in vivo. A recent study in Rhesus Macaques showed that ALVAC induced distinct cytokine and chemokine levels compared to the vaccinia virus-based vectors MVA and NYVAC and that multiple subsets of peripheral blood mononuclear cells (PBMC) are likely to contribute to the overall response to different poxviruses \[[@CR16]\].

In this study we compared the effects of the capripoxvirus, lumpy skin disease virus (LSDV), the orthopoxvirus, MVA, and the avipoxviruses, CNPV, FWPV, a novel pigeonpox virus (FeP2) \[[@CR26], [@CR27]\] and a novel penguinpox virus (PEPV) \[[@CR27]--[@CR29]\] on host gene expression profiles in the spleens of BALB/c mice. None of these viruses complete their replication cycle in mice.

Results {#Sec2}
=======

Comparison of the host responses to different poxviruses {#Sec3}
--------------------------------------------------------

We compared the differential host gene expression induced by six host-restricted poxviruses, MVA, LSDV, FWPV, CNPV, FeP2 and PEPV, in the spleens of BALB/c mice 24 h post infection. Transcripts with an adjusted *p*-value \< 0.05 were described as up-regulated if they had a log~2~ fold change (FC) of ≥1, or down-regulated if they had a log~2~FC of ≤ −1. A summary of the number of up and down-regulated genes is given in Table [1](#Tab1){ref-type="table"}. Full gene lists are given in supplementary data (Additional file [1](#MOESM1){ref-type="media"}). Quantitative RT-PCR showed all three housekeeping genes (GAPDH, HPRT and CD51) to be expressed at similar levels to those of the PBS control for all samples. Both IRF7 and Zbp1 were upregulated by all poxviruses tested. IGFbp3 was shown to be downregulated by all viruses. Overall the quantitative RT-PCR was more sensitive than the microarray, but the trend observed in up- and down-regulation of host gene expression was similar for qRT-PCR and microarray analysis.Table 1Summary of the number of significantly up- and down-regulated transcripts with adjusted *p*-value \< 0.05Up-regulated Log~2~ FC \> 1Down-regulated Log~2~ FC \< −1MVA299 (42NA)177 (86NA)LSDV463 (111NA)85 (11NA)FWPV433 (101NA)62 (28NA)CNPV280 (31NA)47 (11NA)FeP220 (1NA)3 (0NA)PEPV68 (6NA)19 (2NA)Genes are described as upregulated if they had a fold change of ≥2, or down-regulated if they had a Log~2~ Fold change of ≤ −1. These included genes that are not annotated and therefore do not have an Entrez ID. The number of genes without annotation are indicated in brackets

Unsupervised hierarchical clustering based on the genes with *p*-value \< 0.05 and log~2~FC above or below cutoff (\>1, \<−1) showed that each virus induced a unique overall response (Fig. [1](#Fig1){ref-type="fig"}). Venn diagrams highlight the number of differences and similarities in the up- and down-regulated genes between the viruses (Fig. [2](#Fig2){ref-type="fig"}). Fig. [2](#Fig2){ref-type="fig"} a and b show the differences in transcripts up (A) and (B) down-regulated respectively between FWPV, CNPV, MVA and LSDV. The Venn diagrams comparing FWPV, CNPV, MVA and LSDV indicate that the majority of up-regulated genes are shared amongst these 4 viruses (Fig. [2](#Fig2){ref-type="fig"}). The down-regulated genes however, appear largely unique, especially for LSDV and MVA (Fig. [2](#Fig2){ref-type="fig"}). FWPV and CNPV down regulate a smaller number of genes in comparison to LSDV and MVA. Comparison of avipoxvirus-induced up- and down-regulated genes shows that FeP2 and PEPV induce significantly less change in host transcript abundance than FWPV and CNPV (Fig. [2](#Fig2){ref-type="fig"}). FeP2 induced the lowest response (Fig. [2](#Fig2){ref-type="fig"}, Table [1](#Tab1){ref-type="table"}). For all six viruses, more genes were up-regulated than down-regulated (Table [1](#Tab1){ref-type="table"}).Fig. 1Heatmap comparing the differential expression induced in mouse spleens in response to pigeonpox (FeP2), penguinpox (PEPV), lumpy skin disease virus (LSDV), modified vaccinia Ankara (MVA), canarypox virus (CNPV) and fowlpox virus (FWPV). Only genes (with *p*-value \< 0.05) with log~2~ fold change induction above or below the cutoff (±1) as compared to the mock infected control are shown. Unsupervised hierarchical clustering of the samples is represented by dendograms. Clustering analysis and heatmap was performed in the R package, gplots (Warnes, 2009)Fig. 2Venn diagrams showing the overlap between the differentially up-regulated (**a**) and down-regulated (**b**) transcripts induced by canarypox virus (CNPV), fowlpox virus (FWPV), modified vaccinia Ankara (MVA) and lumpy skin disease virus (LSDV) and the up-regulated (**c**) and down-regulated (**d**) transcripts induced by the four avipoxviruses. For each diagram, the circles represent the number of differently expressed transcripts regulated by each virus (*p* value ≤ 0.05, log~2~ fold change of ≥ ±1). The numbers in the intersections of each circle represents the number of transcripts common to the respective virus/es

### Histone transcripts {#Sec4}

Previous studies have found that increased detection of histone genes by poxvirus infection is described as an experimental artefact due to the de novo polyadenylation of transcripts by the viral poly-A polymerase \[[@CR30], [@CR31]\]. Several histone transcripts (39 in total) were down-regulated in response to virus infection and, because any interpretation of these transcripts would be speculative, these have been excluded from further analysis.

Immunity and host defence response-related genes {#Sec5}
------------------------------------------------

### Up-regulated immune response genes {#Sec6}

Selected up-regulated genes involved in the immune response are listed in Table [2](#Tab2){ref-type="table"}. (Full list of up-regulated genes is given in Additional file [1](#MOESM1){ref-type="media"}). Seventeen of these genes are uniquely up-regulated by LSDV. RIG-I (Ddx58) senses viral nucleic acid \[[@CR32]\], Cebpb is important for macrophage function \[[@CR33]\] and control of inflammatory responses \[[@CR34]\], Tap1 and Tap2 genes are involved in antigen presentation to MHC class 1 molecules \[[@CR35]\], Ifitm3 and Ifi203 are interferon responsive genes (ISG), c-Myc and Mif are transcription factors and Adar is an RNA editing enzyme. There are eight genes induced by CNPV, FWPV and MVA, which were not up-regulated in LSDV-infected mice. Two of these include the cytidine deaminase, Apobec1, which can edit viral nucleic acid and can thereby limit viral replication \[[@CR36]\], and Caspase 1 (Casp1), which is associated with pyroptosis (Table [2](#Tab2){ref-type="table"}).Table 2Selection of up-regulated genes in mouse spleens in response to MVA, LSDV, CNPV, FWPV, PEPV and FeP2. Differences in Log~2~ Fold Changes (between each virus and the control) are depicted.SymbolNameEntrezMVALSDVCNPVFWPVPEPVFeP2**Genes induced by LSDV alone***Oas1b2′-5′ oligoadenylate synthetase 1B23961-1.6----Adaradenosine deaminase, RNA-specific56417-1*\-\-\--*CebpbCCAAT/enhancer binding protein (C/EBP), beta12608-1----Ddx58 (RIG-1)DEAD (Asp-Glu-Ala-Asp) box polypeptide 58230073-1.3----Grngranulin14824-1.1----Gvin1GTPase, very large interferon inducible 174558-1.5----Gm17757GTPase, very large interferon inducible 1 pseudogene100417829-1.5----H2-T24histocompatibility 2, T region locus 2415042-1.2----Ifi203interferon activated gene 20315950-1.1----Ifitm3interferon induced transmembrane protein 366141-1.4----Ifi27l2ainterferon, alpha-inducible protein 27 like 2A76933-1.9----Ly6ilymphocyte antigen 6 complex, locus I57248-1----Mifmacrophage migration inhibitory factor17319-1.1----Mycmyelocytomatosis oncogene17869-1.1----Nlrc5NLR family, CARD domain containing 5434341-1.8----Slfn2schlafen 220556-1.1----*Stat1signal transducer and activator of transcription 120846-1.4\-\-\--*Tap1transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)21354-1.1----Tap2transporter 2, ATP-binding cassette, sub-family B (MDR/TAP)21355-1----Trim25tripartite motif-containing 25217069-1----Trim34btripartite motif-containing 34B434218-1.1----***Genes induced by CNPV, FWPV and MVA only, and not LSDV.***[Casp1]{.ul}[caspase 1]{.ul}[12362]{.ul}[1.1]{.ul}[-]{.ul}[1.2]{.ul}[1.1]{.ul}[-]{.ul}[-]{.ul}[Clec4a2]{.ul}[C-type lectin domain family 4, member a2]{.ul}[26888]{.ul}[1.2]{.ul}[-]{.ul}[1.5]{.ul}[1.1]{.ul}*\--*[Ifi205]{.ul}[interferon activated gene 205]{.ul}[226695]{.ul}[1.4]{.ul}[-]{.ul}[1.6]{.ul}[1.8]{.ul}[-]{.ul}[-]{.ul}[Prdx1]{.ul}[peroxiredoxin 1]{.ul}[18477]{.ul}[1]{.ul}[-]{.ul}[1]{.ul}[1.2]{.ul}[-]{.ul}[-]{.ul}[Pnpt1]{.ul}[polyribonucleotide nucleotidyltransferase 1]{.ul}[71701]{.ul}[1.1]{.ul}[-]{.ul}[1.1]{.ul}[1.4]{.ul}[-]{.ul}[-]{.ul}[Scimp]{.ul}[SLP adaptor and CSK interacting membrane protein]{.ul}[327957]{.ul}[1.2]{.ul}[-]{.ul}[1.2]{.ul}[1.5]{.ul}[-]{.ul}[-]{.ul}***Genes induced by avipoxviruses only (CNPV, FWPV, FEP2 and/ or PEPV)Anxa1annexin A116952--1.61.8--Apobec1apolipoprotein B mRNA editing enzyme, catalytic polypeptide 111810--1.21.2--Ccl6chemokine (C-C motif) ligand 620305--1.31.3--Ear2eosinophil-associated, ribonuclease A family, member 213587--1.31.5--Hsbp1heat shock factor binding protein 168196--1.21.2--IghgImmunoglobulin heavy chain (gamma polypeptide)380794--1.51.6--Ighg3Immunoglobulin heavy constant gamma 3380795--1.31.2--Lilrb3leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 318733--1.11--Marcomacrophage receptor with collagenous structure17167--1-1.51.5Pf4platelet factor 456744--1.21.1--Pram1PML-RAR alpha-regulated adaptor molecule 1378460--1.11.1--Psma1proteasome (prosome, macropain) subunit, alpha type 126440--1.11.3--Genes induced by FWPV only.*Aif1**allograft inflammatory factor 1**11629**-**-**-**1.1**-**-**Anxa2**annexin A2**12306**-**-**-**1.1**-**-**Ddx18**DEAD (Asp-Glu-Ala-Asp) box polypeptide 18**66942**-**-**-**1.1**-**-**Dcn**decorin**13179**-**-**-**1.5**-**-**Fgl2**fibrinogen-like protein 2**14190**-**-**-**1.2**-**-**Gsdmd**gasdermin D**69146**-**-**-**1.2**-**-**Myd88**myeloid differentiation primary response gene 88**17874**-**-**-**1.2**-**-**Nos2**nitric oxide synthase 2, inducible**18126**-**-**-**1.1**-**-**Nod1**nucleotide-binding oligomerization domain containing 1**107607**-**-**-**1**-**-**Pdcd5**programmed cell death 5**56330**-**-**-**1.2**-**-**Psmc6**proteasome (prosome, macropain) 26S subunit, ATPase, 6**67089**-**-**-**1**-**-**Prmt1**protein arginine N-methyltransferase 1**15469**-**-**-**1**-**-**Serpinb6b**serine (or cysteine) peptidase inhibitor, clade B, member 6b**20708**-**-**-**1.2**-**-*Genes induced by CNPV only.[Ctsl]{.ul}[cathepsin L]{.ul}[13039]{.ul}[-]{.ul}[-]{.ul}[1.1]{.ul}[-]{.ul}[-]{.ul}[-]{.ul}[Ighm]{.ul}[immunoglobulin heavy constant mu]{.ul}[16019]{.ul}[-]{.ul}[-]{.ul}[1.1]{.ul}[-]{.ul}[-]{.ul}[-]{.ul}[Ly96]{.ul}[lymphocyte antigen 96]{.ul}[17087]{.ul}[-]{.ul}[-]{.ul}[1.2]{.ul}[-]{.ul}[-]{.ul}[-]{.ul}[Pomp]{.ul}[proteasome maturation protein]{.ul}[66537]{.ul}[-]{.ul}[-]{.ul}[1]{.ul}[-]{.ul}[-]{.ul}[-]{.ul}Genes induced by LSDV AND MVA, but not by the AVIPOXVIRUSES**[Hsh2dhematopoietic SH2 domain containing2094881.11.4]{.ul}\-\-\--[Mov10Moloney leukemia virus 10174541.11.5----Parp11poly (ADP-ribose) polymerase family, member 1110118711.4]{.ul}\-\-\--[Slfn8schlafen 82769501.21.5----]{.ul}**Other**Oas1a2′-5′ oligoadenylate synthetase 1A2467301.52.71.61.4\--Oas1g2′-5′ oligoadenylate synthetase 1G239602.33.92.52.3\--Oas22′-5′ oligoadenylate synthetase 22467282.13.421.6\--Oas32′-5′ oligoadenylate synthetase 32467271.12.61.31\--Oasl12′-5′ oligoadenylate synthetase-like 12316552.63.52.42.5\--Oasl22′-5′ oligoadenylate synthetase-like 22396223.422\--Amica1adhesion molecule, interacts with CXADR antigen 1270152-1.1-1.1\--Angptl4angiopoietin-like 4578751.11.5-1.61.1-Asb13ankyrin repeat and SOCS box-containing 131426881.211.11.3\--Anxa4annexin A4117461.81.91.72.11.1-Apol9bapolipoprotein L 9b718982.32.72.62.4\--Bst2bone marrow stromal cell antigen 2695502.332.12.2\--Casp4caspase 4, apoptosis-related cysteine peptidase123631.91.61.92\--Ctsccathepsin C130321.11.1-1.1\--Cd274CD274 antigen605331.92.31.62.11.2-Cd5lCD5 antigen-like118011.21.51.41.1\--Cd69CD69 antigen125151.81.81.51.7\--Ccl2 (MCP1)chemokine (C-C motif) ligand 2202963.53.32.93.32.8-Ccl3 (MIP-1α)chemokine (C-C motif) ligand 32030222.12.321.4-Ccl7chemokine (C-C motif) ligand 72030632.92.62.92.71.5Ccr5chemokine (C-C motif) receptor 5127741.11.51.31.3\--Ccrl2chemokine (C-C motif) receptor-like 254199-1.51.21.4\--Cxcl10 (IP-10)chemokine (C-X-C motif) ligand 10159452.732.22.81.7-Cxcl11 (I-TAC)chemokine (C-X-C motif) ligand 11560664.54.43.44.31.5-Cxcl9 (MIG)chemokine (C-X-C motif) ligand 9173292.12.3-1.8\--Chi3l3chitinase 3-like 312655-1.21.41.6\--Csf2rb2colony stimulating factor 2 receptor, beta 2, low-affinity (granulocyte-macrophage)12984-1.5-1.7\--C1qacomplement component 1, q subcomponent, alpha polypeptide12259-1.11\-\--C2complement component 2 (within H-2S)122631.51.81.71.61-Cfbcomplement factor B149622.22.61.621-Cdkn1a (P21)cyclin-dependent kinase inhibitor 1A125751.721.521.2-Cstbcystatin B130141.411.51.5\--Cst7cystatin F (leukocystatin)130111.21.41.11.4\--Cmpk2cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial221691.321.31.3\--Cycscytochrome c, somatic13063-1.1-1.1\--Ctla2acytotoxic T lymphocyte-associated protein 2 alpha130241.111.11.3-1.4Ddx60DEAD (Asp-Glu-Ala-Asp) box polypeptide 602343111.72.61.51.4\--Dhx58 (LGP2)DEXH (Asp-Glu-X-His) box polypeptide 58808611.72.51.61.5\--Dram1DNA-damage regulated autophagy modulator 1717121.21.4-1.3\--Ddit4DNA-damage-inducible transcript 4747471.21.21.81.31.4-Eif2ak2 (PKR)eukaryotic translation initiation factor 2-alpha kinase 2191061.12.11.11.1\--DaxxFas death domain-associated protein1316322.31.71.9\--Fcgr1Fc receptor, IgG, high affinity I141292.42.62.42.61.4-Fcgr4Fc receptor, IgG, low affinity IV2462562.53.62.82.91.8-Fpr1formyl peptide receptor 1142931.31.11.41.4\--Fpr2formyl peptide receptor 2142891.81.51.71.9\--Glipr2GLI pathogenesis-related 23840091.41.51.11.5\--Gp49aglycoprotein 49 A147272.62.42.72.71.92Gcagrancalcin2279601.21.31.41.6\--Gzmagranzyme A149381.81.82.22\--Gzmbgranzyme B149393.74.74.14.22.4-Gadd45bgrowth arrest and DNA-damage-inducible 45 beta178731.31.51.21.5\--Gbp1guanylate binding protein 1144682.12.71.62.5\--Gbp11guanylate binding protein 116346503.94.52.94.21.6-Gbp2guanylate binding protein 2144692.32.81.52.7\--Gbp3guanylate binding protein 3559321.61.81.21.6\--Gbp4guanylate binding protein 4174722.12.71.32.4\--Gbp5guanylate binding protein 522989822.81.32.21.1-Gbp7guanylate binding protein 72299001.62.21.21.7\--Gbp10guanylate-binding protein 106265782.13.21.31.9\--Gbp8guanylate-binding protein 8760741.31.41.42.1\--Gbp9guanylate-binding protein 92365731.21.911.3\--Hphaptoglobin154391.21.81.71.91.31.3Hspa1bheat shock protein 1B155112.32.92.42.5\--H2-Q4histocompatibility 2, Q region locus 41501511.2-1.2\--H2-Q6histocompatibility 2, Q region locus 611055711-1.1\--H2-T22histocompatibility 2, T region locus 221503911.3\-\-\--H2-T23histocompatibility 2, T region locus 231504011.3-1\--Irgm1immunity-related GTPase family M member 1159441.42.31.11.4\--Irgm2immunity-related GTPase family M member 25439611.7-1.2\--Irg1immunoresponsive gene 1163652.62.51.92.51.6-Ifi202binterferon activated gene 202B263882.42.62.12.2\--Ifi204interferon activated gene 204159513.343.23.9\--Igtpinterferon gamma induced GTPase161451.42.211.8\--Ifitm6interferon induced transmembrane protein 62130021.81.92.42.31.61.5Ifih1 (MDA5)interferon induced with helicase C domain 1715861.32.11.21.2\--Iigp1interferon inducible GTPase 1604401.72.91.21.9\--Irf1interferon regulatory factor 116362-1.3-1.1\--Irf7interferon regulatory factor 7541231.72.91.71.1\--Ifi35interferon-induced protein 35701101.11.51.11.2\--Ifi44interferon-induced protein 449989922.51.81.6\--Ifi44linterferon-induced protein 44 like150612.12.922\--Ifit1interferon-induced protein with tetratricopeptide repeats 1159572.23.321.7\--Ifit2interferon-induced protein with tetratricopeptide repeats 2159581.82.51.81.7\--Il1ainterleukin 1 alpha161751.922.22.31.8-Il1f9interleukin 1 family, member 92152571.31.61.71.81.21Il1rninterleukin 1 receptor antagonist161811.31.1-1.2\--Il12rb1interleukin 12 receptor, beta 11616122.41.72.11.1-Il12rb2interleukin 12 receptor, beta 2161621.21.31.31.3\--Il15interleukin 15161681.11.31.21\--Il15rainterleukin 15 receptor, alpha chain161691.81.91.51.81.2-Il18bpinterleukin 18 binding protein160681.21.71.31.5\--Il2rainterleukin 2 receptor, alpha chain161841.11.2-1.31.1-Il33interleukin 3377125-1-1.1\--Isg15ISG15 ubiquitin-like modifier1000388821.62.21.51.4\--Klrk1killer cell lectin-like receptor subfamily K, member 1270071.51.71.61.5\--Lgals9lectin, galactose binding, soluble 9168591.21.61.11.2\--Lgals3bplectin, galactoside-binding, soluble, 3 binding protein190391.21.71.1\-\--Lilrb4leukocyte immunoglobulin-like receptor, subfamily B, member 4147281.61.51.71.71.1-Lcn2lipocalin 2168191.41.62.22.21.41.7Ly6alymphocyte antigen 6 complex, locus A1104541.71.91.21.3\--Ly6c1lymphocyte antigen 6 complex, locus C1170671.82.21.91.9\--Ly6c2lymphocyte antigen 6 complex, locus C21000415461.31.61.31.1\--Ly6glymphocyte antigen 6 complex, locus G546644-1.72.52.2\--Msr1macrophage scavenger receptor 1202882.3222.21.41.1Mmp13matrix metallopeptidase 13173862.72.62.42.41.5-Mmp19matrix metallopeptidase 19582231.92221.51.2Mmp25matrix metallopeptidase 25240047-1-1.1\--Mmp8matrix metallopeptidase 8173942.733.13.42.52.8Ms4a4amembrane-spanning 4-domains, subfamily A, member 4A6669072.62.72.62.51.51.1Ms4a4cmembrane-spanning 4-domains, subfamily A, member 4C643801.21.51.21\--Ms4a4dmembrane-spanning 4-domains, subfamily A, member 4D666071.61.51.61.8\--Ms4a6cmembrane-spanning 4-domains, subfamily A, member 6C736561.11.11.21.2\--Ms4a6dmembrane-spanning 4-domains, subfamily A, member 6D687743.23.53.13.3\--Ms4a7membrane-spanning 4-domains, subfamily A, member 71092251.71.421.91.4-Mlklmixed lineage kinase domain-like745682.12.722.3\--Mndamyeloid cell nuclear differentiation antigen3813081.81.81.61.7\--Mndalmyeloid nuclear differentiation antigen like1E + 081.11.31.11.2\--Mx1myxovirus (influenza virus) resistance 1178573.23.932.8\--Mx2myxovirus (influenza virus) resistance 2178582.73.72.12.2\--Namptnicotinamide phosphoribosyltransferase590271.71.91.52\--NmiN-myc (and STAT) interactor646851.31.61.11.5\--Prf1perforin 1 (pore forming protein)186461.21.41.11.2\--Phf11aPHD finger protein 11A2191311.21.41.11.1\--Phf11bPHD finger protein 11B23645121.81.71.8\--Phf11cPHD finger protein 11C62870522.41.71.7\--Phf11dPHD finger protein 11D2191322.42.92.42.41.1-Plac8placenta-specific 82315071.31.7-1.3\--Parp10poly (ADP-ribose) polymerase family, member 106715351.21.5-1.2\--Parp12poly (ADP-ribose) polymerase family, member 122437711.52.51.31.6\--Parp14poly (ADP-ribose) polymerase family, member 145472531.11.7-1\--Parp9poly (ADP-ribose) polymerase family, member 9802851.31.91.11.2\--Psme1proteasome (prosome, macropain) 28 subunit, alpha19186-1.1-1\--Psma7proteasome (prosome, macropain) subunit, alpha type 726444-1.1-1.1\--Psmb10proteasome (prosome, macropain) subunit, beta type 10191711.11.4-1.3\--Psmb8proteasome (prosome, macropain) subunit, beta type 8 (large multifunctional peptidase 7)16913-1.4-1.1\--Pyhin1pyrin and HIN domain family, member 12363121.71.81.51.4\--Pydc3pyrin domain containing 31000334591.92.41.71.5\--Pydc4pyrin domain containing 46231212.93.42.21.9\--Ppa1pyrophosphatase (inorganic) 1678951.32.1-1.5\--Pdk4pyruvate dehydrogenase kinase, isoenzyme 4272731.51.11.71.41.81.8Rtp4receptor transporter protein 4677751.42.21.21.1\--Retnlgresistin like gamma2451951.11.31.51.61.41.6Rnf19bring finger protein 19B75234-1.2-1.1\--Rnf213ring finger protein 2136725111.42.211\--Slfn1schlafen 1205551.81.91.31.5\--Slfn3schlafen 3205571.31.71.51.7\--Slfn4schlafen 4205581.9321.8\--Slfn5schlafen 53279781.52.41.41.1\--Slfn9schlafen 92378861.52.41.41.7\--Serpina3fserine (or cysteine) peptidase inhibitor, clade A, member 3 F2383931.92.71.32.21.3-Serpinb9serine (or cysteine) peptidase inhibitor, clade B, member 9207231.31.11.11.4\--Serpinb9bserine (or cysteine) peptidase inhibitor, clade B, member 9b207061.211.1\-\--Serpine1serine (or cysteine) peptidase inhibitor, clade E, member 1187871.1\--1\--Stat2signal transducer and activator of transcription 2208471.41.91.21.5\--Slamf8SLAM family member 874748-1.1-1.2\--Slc15a3solute carrier family 15, member 365221-1.3-1.1\--Slc25a22solute carrier family 25 (mitochondrial carrier, glutamate), member 2268267-1.211.2\--Socs1suppressor of cytokine signaling 1127031.62.2-1.9\--Socs2suppressor of cytokine signaling 221623311.4-1.8\--Tgtp1T cell specific GTPase 121822-1.4-1.1\--Tgtp2T cell specific GTPase 21.00E + 081.62.7-1.5\--Trex1three prime repair exonuclease 122040-1.2-1\--Timp1tissue inhibitor of metalloproteinase 1218572.82.92.42.91.81.6Tlr13toll-like receptor 132795721.411.71.51-Tlr3toll-like receptor 314298011.41.21.1\--Tlr7toll-like receptor 71707431.11.21.2\-\--Tlr8toll-like receptor 81707441.11.11.31\--Trafd1TRAF type zinc finger domain containing 12317121.11.611.1\--Trem3triggering receptor expressed on myeloid cells 3582181.11.41.21.5\--Trim12ctripartite motif-containing 12C319236-1.51.21.3\--Trim21tripartite motif-containing 21208211.11.3-1.4\--Trim30atripartite motif-containing 30A201281.32.1-1.1\--Trim30ctripartite motif-containing 30C4342192.63.42.52.2\--Trim30dtripartite motif-containing 30D2093873.13.53.42.71.4-Warstryptophanyl-tRNA synthetase223751.11.6-1.4\--Tnfsf10tumor necrosis factor (ligand) superfamily, member 102203522.321.9\--Usp18ubiquitin specific peptidase 18241102.23.121.8\--Zbp1Z-DNA binding protein 1582031.92.71.31.6\--*Italics*: Genes induced by LSDV alone*Italics and underlined*: Genes induced by CNPV, FWPV and MVA only, and not LSDV**Bold**: Genes induced by Avipoxviruses only (CNPV, FWPV, FeP2 and/ or PEPV)***Bold and Italics***: Genes induced by FWPV only**Bold and underlined**: Genes induced by CNPV only*Underlined*: Genes induced by LSDV and MVA, but not by the Avipoxviruses

Twenty six genes involved in the host immune/defence response were up-regulated only in avipoxvirus-infected mouse spleens (Table [2](#Tab2){ref-type="table"}). The only avipoxvirus-specific gene that was up-regulated by all four avipoxviruses was the macrophage receptor with collagenous structure (Marco) gene which has been shown to suppress early inflammatory responses to virus infection \[[@CR37]\]. There were, however, 9 additional genes which were up-regulated by both CNPV and FWPV that were not induced by the other viruses. These included the chemokine Ccl6 which promotes immune cell activation and recruitment \[[@CR38]\] and the immunoglobulin heavy chain genes, Ighg (IgG) and Ighg3 (IgG3) (Table [2](#Tab2){ref-type="table"}). Amongst these 26 avipoxvirus-specific genes, 14 were exclusively up-regulated by FWPV. The Nod-like receptor, NLR, Nod1, which has been shown to be augmented in response to virus-induced production of type I IFNs \[[@CR39]\] was exclusively up-regulated by FWPV. Four genes were uniquely up-regulated in CNPV-infected mice including the immunoglobulin heavy chain gene, Ighm (IgM), lymphocyte antigen 96 (Ly96), proteasome maturation protein (Pomp) and Cathepsin L (Ctsl) (Table [2](#Tab2){ref-type="table"}). PePV and FeP2 induced very little immune activation according to this microarray analysis.

Four genes were up-regulated by LSDV and MVA that were not induced by the avipoxviruses in mice (Table [2](#Tab2){ref-type="table"}), namely the Moloney Leukemia Virus 10 (Mov10) gene, hematopoietic SH2 domain containing protein (Hsh2d), poly (ADP-ribose) polymerase family, member 11 (Parp11) and schlafen 8 (Slfn8). No genes were uniquely up-regulated in response to MVA infection (Table [2](#Tab2){ref-type="table"}).

### Down-regulated immune related genes {#Sec7}

Selected down-regulated genes involved in the immune response are listed in Table [3](#Tab3){ref-type="table"}. Full lists of down-regulated genes in response to each virus are given in Additional file [1](#MOESM1){ref-type="media"}. MVA and LSDV induced the down regulation of several genes that were not affected in avipoxvirus-infected spleens. These included three forms of the chemokine CCL21 (Ccl21a, Ccl21b, Ccl21c) which are potent chemoattractants for lymphocytes and dendritic cells \[[@CR40]\] (Table [3](#Tab3){ref-type="table"}). Furthermore, MVA and LSDV down regulate the high affinity IgM and IgA F~C~ receptor Fcamr. Fcamr is the receptor for the F~C~ fragment of immunoglobulins IgA and IgM \[[@CR41]\]. Interestingly, MVA, LSDV, FWPV and CNPV all down regulate the gene encoding the murine homolog for DC-specific ICAM-3--grabbing nonintegrin (DC SIGN) (Cd209a), and MVA and LSDV down regulate an additional DC SIGN homolog, CD209b (SIGNR1) (Table [3](#Tab3){ref-type="table"}). LSDV uniquely down regulates CD59a, which is the primary regulator of complement membrane attack in mouse \[[@CR42]\] and CD7 which is expressed on T- and NK cells, and on cells in the early stages of T, B, and myeloid cell differentiation \[[@CR43]\]. LSDV also uniquely down regulates the immunoglobulin kappa chain complex (IgK) amongst other immune related genes (Table [3](#Tab3){ref-type="table"}). TLR11 is down-regulated by MVA alone (Table [3](#Tab3){ref-type="table"}).Table 3Selection of down-regulated genes in mouse spleens in response to MVA, LSDV, CNPV, FWPV, PEPV and FeP2. Differences in Log~2~ Fold Changes (between each virus and the control) are depictedSymbolNameEntrezMVALSDVCNPVFWPVPEPVFeP2**Genes down-regulated by LSDV ALONE*Adamdec1****ADAM-like, decysin 158860-−1.1----****Cd59a****CD59a antigen12509-−1.2----****Cd7****CD7 antigen12516-−1.1----****Esm1****endothelial cell-specific molecule 171690-−1.1----****Igfbp3****insulin-like growth factor binding protein 316009-−1----****Igk****immunoglobulin kappa chain complex243469-−1----****Lilra5****leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 5232801-−1.1----****Prkcg****protein kinase C, gamma18752-−1----***Genes down-regulated by MVA aloneCtsfcathepsin F56464−1.1-----Depdc1aDEP domain containing 1a76131−1.1-----Diap3diaphanous homolog 3 (Drosophila)56419−1.1-----Hmmr (CD168)hyaluronan mediated motility receptor (RHAMM)15366−1-----Tlr11toll-like receptor 11239081−1-----Genes down-regulated by lsdv and MVA, BUT NOT BY CNPV and FWPV[Ccl21a]{.ul}**[chemokine (C-C motif) ligand 21A (serine)18829−1.3−1.7]{.ul}\-\-\--**[Ccl21b]{.ul}**[chemokine (C-C motif) ligand 21B (leucine)100042493−1.2−1.7]{.ul}\-\-\--**[Ccl21c]{.ul}**[chemokine (C-C motif) ligand 21C (leucine)65956−1.2−1.6]{.ul}\-\-\--**[Kel]{.ul}**[Kell blood group23925−1.5−1.5]{.ul}\-\-\--**[Slc12a2]{.ul}**[solute carrier family 12, member 220496−1−1----]{.ul}**[Timd4]{.ul}**[T cell immunoglobulin and mucin domain containing 4276891−1.1−1.3----]{.ul}**Genes down-regulated by CNPV, FWPV AND MVA ONLY, and not LSDV.*[Tspan33]{.ul}****[tetraspanin 33]{.ul}[232670]{.ul}[−1.6]{.ul}[-]{.ul}[−1.3]{.ul}[−1.1]{.ul}[-]{.ul}[-]{.ul}***OTHERAbca9**ATP-binding cassette, sub-family A (ABC1), member 9217262−1.3−1.5-−1.1\--**Aplnr**apelin receptor23796−1.4−1.5−1.2−1.2\--**Cd209a**CD209a antigen170786−1.7−2.2−1.1−1.5\--**Cd209b**CD209b antigen69165−1.2−1.3\-\-\--**Cldn13**claudin 1357255−1.5−1.2−1.1\-\--**Emr4**EGF-like module containing, mucin-like, hormone receptor-like sequence 452614−1.4−1.8−1.1−1.5−1.3-**Fcamr**Fc receptor, IgA, IgM, high affinity64435−1.1-−1.5\-\--**Fcer2a**Fc receptor, IgE, low affinity II, alpha polypeptide14128−2.6−3−2.4−2.5−2.2−1.3**H2-M2**histocompatibility 2, M region locus 214990−1−1.4−1−1−1.1-**Hs3st2**heparan sulfate (glucosamine) 3-O-sulfotransferase 2195646−1.4−1.3−1−1\--**Ifi27l1**interferon, alpha-inducible protein 27 like 152668−1.4−1.3\-\-\--**Mgst3**microsomal glutathione S-transferase 366447−1.6−1-−1\--**Slc16a10**solute carrier family 16 (monocarboxylic acid transporters), member 1072472−1.4\--−1.1\--**Slc2a4**solute carrier family 2 (facilitated glucose transporter), member 420528−1.7−1-−1.1\--**Slc38a5**solute carrier family 38, member 5209837−1.4−1.2−1\-\--**Slc6a20a**solute carrier family 6 (neurotransmitter transporter), member 20A102680−1.4−1.3−1−1\--**Tfrc**transferrin receptor22042−1.2\-\-\-\--**Tspan8**tetraspanin 8216350−1.4\--−1\--*Italics* genes down-regulated by LSDV alone*Bold* Genes down-regulated by MVA alone*Underlined* genes down-regulated by LSDV and MVA, but not by avipoxviruses*Italics and underlined* genes down-regulated by CNPV, FWPV and MVA only, and not LSDV

### Type I interferon response {#Sec8}

While many of the immunity related genes listed in Table [2](#Tab2){ref-type="table"} are regulated in some way by Type I Interferons, in order to characterise and compare the differences in the Type I IFN-regulated responses between MVA, LSDV, FWPV, CNPV, FeP2 and PEPV at 24 h, we analyzed a selection of genes known to be involved in the IFN response \[[@CR44]--[@CR46]\] (Fig. [3](#Fig3){ref-type="fig"}). This figure clearly shows that LSDV induces the greatest IFN response compared to the other viruses (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Heatmap (**a**) and radial plot (**b**) depicting the differences in the type I Interferon response induced by canarypox virus (CNPV), pigeonpox (FeP2), fowlpox virus (FWPV), lumpy skin disease virus (LSDV), modified vaccinia Ankara (MVA) and penguinpox virus (PEPV). Fig. 3. **a** represents the log~2~ fold change (FC) induction of the different genes up-regulated in the six samples compared to the control. A log~2~FC of 0 is given where genes are not present over the cut off (±1). Unsupervised hierarchical clustering of the samples is represented by dendograms. Clustering analysis and heatmap was performed in the R package, gplots (Warnes, 2009). Fig. 3. **b** shows a radial plot depicting the magnitude and breadth of the type I interferon response induced by the six viruses. The distance from the centre of the plot indicates log2-fold change (ranging from −2 to 4)

### Caspases {#Sec9}

MVA, FWPV and CNPV all up-regulated the protease caspase 1 (casp1) whereas LSDV did not (Fig. [4](#Fig4){ref-type="fig"}). MVA, FWPV, CNPV and LSDV significantly up-regulated caspase 4 (casp 4) (historically called caspase 11 in the mouse) (Table [2](#Tab2){ref-type="table"}). The SA avipoxviruses, FeP2 and PEPV did not affect gene regulation of any caspase genes.Fig. 4**a** T-cell specific responses and 4**b**) B-cell specific responses up- or down-regulated in mouse spleens in response to canarypox virus (CNPV), pigeonpox (FeP2), fowlpox virus (FWPV), lumpy skin disease virus (LSDV), modified vaccinia Ankara (MVA) and penguinpox virus (PEPV). The log~2~ fold changes of significantly differentially expressed (*p* value ≤ 0.05) genes involved in the respective types of responses are compared. A value of 0 indicates that no change was observed compared to mock infected mouse spleens. A positive value depicts upregulated genes and a negative value depicts down-regulated genes

### B- and T-cell specific responses {#Sec10}

The up- and down-regulated genes involved in B cell and T cell responses induced by the viruses in this study were compared (Fig. [4](#Fig4){ref-type="fig"}). Fig. [4a](#Fig4){ref-type="fig"} highlights the regulated genes that are involved in the T cell response. FeP2 and PEPV regulated only one gene each involved in this response, Ctla2a and major histocompatibility (MHC) class I gene, H2-M2, respectively. The other four viruses differentially regulated several MHC class I genes amongst others (Fig. [4a](#Fig4){ref-type="fig"}). As highlighted in Table [2](#Tab2){ref-type="table"}, the avipoxviruses, CNPV and FWPV, exclusively up regulate immunoglobulin heavy chain genes, (Ighg (IgG) and Ighg3 (IgG3)) with CNPV inducing a third, Ighm (IgM) (Fig. [4b](#Fig4){ref-type="fig"}). LSDV down regulates the immunoglobulin kappa (IgK) chain complex (Fig. [4b](#Fig4){ref-type="fig"}). In addition to these, the poxviruses differentially regulate genes for F~C~ receptors and complement (Fig. [4b](#Fig4){ref-type="fig"}).

### Comparison of early poxvirus-induced immune responses to innate molecular signatures of published candidate vaccine vectors {#Sec11}

We compared the gene expression induced by each of the 6 poxviruses at 24 h to selected correlates of protection and molecular signatures from previously published studies (Table [4](#Tab4){ref-type="table"}). The induction of multiple PRRs has been shown to activate different immune pathways and thereby induce a more polyvalent immune response \[[@CR47], [@CR48]\]. We identified differential expression of several genes involved in pathogen recognition (Table [4](#Tab4){ref-type="table"}). Several genes are common to the innate and adaptive immune responses induced by the poxviruses analysed here and other viral vectors analysed elsewhere (Table [4](#Tab4){ref-type="table"}).Table 4Comparison of early poxvirus-induced immune responses to selected innate molecular signatures of existing vaccine vectors. Differences in Log~2~ Fold Changes (between each virus and the control) are depicteddescriptionMVALSDVCNPVFWPVPEPVFeP2EvidenceReferences**Innate immune response*Pathogen recognition*Tlr13**toll-like receptor 131.41.01.71.51.0-**Tlr3**toll-like receptor 311.41.21.1\--Merck Ad5/HIV\[[@CR22]\]**Tlr7**toll-like receptor 71.11.21.2\-\--YF-17D, LAIV\[[@CR20], [@CR21]\]**Tlr8**toll-like receptor 81.11.11.31.0\--Merck Ad5/HIV\[[@CR22]\]**Tlr11**toll-like receptor 11−1.0\-\-\-\--**Ddx58 (RIG-I)**RIG-I-like receptor-1.3\-\-\--YF-17D\[[@CR20]\]**Cd209a (DC SIGN)**CD209a antigen−1.7−2.2−1.1−1.5\--**Cd209b (DC SIGN)**CD209b antigen−1.2−1.3\-\-\--**Ifih1 (MDA5)**RIG-I-like receptor1.32.11.21.2\--YF-17D\[[@CR20]\]**Zbp1 (DAI)**cytoplasmic double-stranded DNA sensor1.92.71.31.6\--**Dhx58 (LGP2)**RIG-I-like receptor1.72.51.61.5\--YF-17D\[[@CR20]\]**Eif2ak2 (PKR)**eukaryotic translation initiation factor 2-alpha kinase 2 (protein kinase R)1.12.11.11.1\--YF-17D\[[@CR20]\]***Genes associated with the innate immune response of viral vectors*Cxcl10 (IP-10)**chemokine (C-X-C motif) ligand 102.732.22.81.7-Significantly upregulated in response to YF-17D, Merck Ad5/HIV, TIV\[[@CR20]−[@CR22]\]**Mx1**myxovirus (influenza virus) resistance 13.23.932.8\--YF-17D\[[@CR20]\]**Il-1α**interleukin 1 alpha1.922.22.31.8-Significantly upregulated in response to YF-17D**Isg15**ISG15 ubiquitin-like modifier1.62.21.51.4\--Merck Ad5/HIV\[[@CR22]\]**Stat1**signal transducer and activator of transcription 1-1.4\-\-\--YF-17D, Merck Ad5/HIV, LAIV\[[@CR20]−[@CR22]\]**Cxcl11 (I-TAC)**chemokine (C-X-C motif) ligand 114.54.43.44.31.5-Merck Ad5/HIV\[[@CR22]\]**Ccr5**chemokine (C-C motif) receptor 51.11.51.31.3\--Merck Ad5/HIV\[[@CR22]\]**Gbp7**guanylate binding protein 71.62.21.21.7\--Merck Ad5/HIV\[[@CR22]\]**Irf1**interferon regulatory factor 1-1.3-1.1\--Merck Ad5/HIV\[[@CR22]\]**Stat2**signal transducer and activator of transcription 21.41.91.21.5\--LAIV\[[@CR21]\]**Irf7**interferon regulatory factor 71.72.91.71.1\--LAIV\[[@CR21]\]**Casp1**caspase 11.1-1.21.1\--**Adaptive immune responseB cell related responsesIghg**Immunoglobulin heavy chain (gamma polypeptide)\--1.51.6\--**Ighg3**Immunoglobulin heavy constant gamma 3\--1.31.2\--TIV, correlated with decreased risk of HIV-1 infection in the RV144 trial ALVAC-HIV(vCP1521)**Ighm**immunoglobulin heavy constant mu\--1.1\-\--positively correllates with antibody response to TIV\[[@CR21]\]**Igk**immunoglobulin kappa chain complex-−1.0\-\-\--positively correllates with antibody response to TIV\[[@CR21]\]**T cell related responsesGzmb**granzyme B3.74.74.14.22.4-expressed by CD8+ T cells in response to YF-17D\[[@CR20]\]**Ccr5**chemokine (C-C motif) receptor 51.11.51.31.3\--expressed by CD8+ T cells in esponse to YF-17D\[[@CR20]\]**Ccl2 (MCP1)**chemokine (C-C motif) ligand 23.53.32.93.32.8-predicted the magnitude of the CD8+ T cell response to Merck Ad5/HIV\[[@CR22]\]*HIV* human immunodeficiency virus, *LAIV* live attenuated influenza vaccine, *TIV* trivalent influenza vaccine, *YF-17D* Yellow fever vaccine, *Merck Ad5/HIV* Merck's Adenovirus subtype 5-based HIV vaccine

Discussion {#Sec12}
==========

Novel avipoxviruses have been isolated in South Africa with the goal of identifying novel vaccine vectors \[[@CR26], [@CR27]\]. It is desirable to be able to select potential avipoxvirus vaccine vectors without going through the process of making recombinant viruses and testing immunogenicity in animal models. In this study, we compared the gene expression profiles in mouse spleens 24 h after infection with six poxviruses from 3 different genera. All the viruses were grown in eggs and the same purification methodology used. There have been no comparisons of host responses to these six different poxviruses. One of the aims of this study was to determine if one could select novel poxvirus vaccine vectors based on the transcriptome analysis. It was hypothesized that if the transcriptomes were identical then it was unlikely that they would differ as vaccine vectors. The complex model of the mouse spleen was selected because the spleen is rich in immune cells and the immune response is a complex interaction between different types of cells and their proteins which would not be reflected in in vitro models. Although in vitro expression studies have provided useful information, gene expression profiles performed in cell culture may not accurately reflect the changes that occur as result of infection in vivo. It is anticipated that different poxviruses will have different properties that will relate to their ability to act as adjuvants driving the immune response to the vaccine protein towards a particular type of immune response.

Unsupervised hierarchical clustering differentiates between the observed responses to the six poxviruses, grouping CNPV and MVA together and FWPV in a separate cluster (more closely related to CNPV and MVA than to LSDV) (Fig. [1](#Fig1){ref-type="fig"}). FeP2 and PEPV group together in a cluster that is separate from the other four viruses (Fig. [1](#Fig1){ref-type="fig"}). This grouping is quite different from phylogenetic relationships established by DNA sequence comparisons \[[@CR27]\]. It is also not dependent on the viral morphogenesis in non-permissive cells. PEPV and FWPV have been demonstrated to infect mammalian cells \[[@CR28]\] and progress to a late stage in morphogenesis \[[@CR28], [@CR49]\] whereas FeP2 \[[@CR50]\] and CNPV have a block prior to DNA replication \[[@CR51]\]. It is noted that infectivity studies have not been done in mouse spleens and that this may be different to published data on other mammalian cells. A further study is needed to determine if PEPV and FeP2 infect the same number of cells in the mouse spleen as the other viruses.

Amongst the four avipoxviruses analysed here, the greatest difference in host responses was expected between CNPV and FWPV, as on a genomic level, these viruses are significantly divergent with amino acid identity between ORF homologues (55--74 %) being similar to that observed between different ChPV genera \[[@CR52]\]. We did not expect to see such significant differences between the host responses induced by FeP2 and PEPV which share 94.4 % nucleotide identity with each other and 85.3 and 84.0 % nucleotide identity with FWPV respectively \[[@CR27]\]. Since avipoxviruses are restricted to avian hosts, one would anticipate fewer differences between the mammalian host responses induced by them as it is highly likely that their proteins are not as functional in mammalian cells as those of MVA and LSDV. However we show that three relatively closely related avipoxviruses (FWPV, FeP2 and PEPV) induce significant differences in gene expression in the host. FWPV induced the strongest host response in mice whereas FeP2 infection resulted in remarkably little change in host gene expression. A vaccine vector with low host reactivity, such as observed with PEPV or FeP2, might have the advantage of being a good vector to include adjuvant genes to enhance immunogenicity. Further investigation is needed to determine if there would be a good immune response to foreign antigens expressed by these vectors.

Previous in vitro studies with VACV, MVA and NYVAC have shown more host genes to be down-regulated than up-regulated \[[@CR11]--[@CR14]\]; however, this was not the case in other poxviruses, including cowpox virus (CPXV) \[[@CR53]\], monkeypox virus (MPXV) \[[@CR53]\] or ALVAC \[[@CR15]\]. Unlike our study, done in a mouse model, all these studies were done in cell culture. We show that fewer genes are down-regulated than up-regulated in response to in vivo infection at 24 h post infection (Table [1](#Tab1){ref-type="table"}). For each poxvirus tested several of the dysregulated mouse genes are not yet annotated suggesting biological roles for unannotated genes and highlighting the importance of further functional analysis and annotation of the mouse genome. Contrary to in vitro studies, MVA caused more transcripts to be up-regulated than down-regulated in mouse spleens. MVA infection did, however, result in a greater number of down-regulated transcripts compared to LSDV, FWPV and CNPV.

MVA and LSDV induced the down-regulation of several genes that were not affected by the avipoxviruses tested including three forms of the chemokine CCL21 (Ccl21a, Ccl21b, Ccl21c) which are potent chemoattractants for lymphocytes and dendritic cells \[[@CR40]\] (Table [3](#Tab3){ref-type="table"}). VACV A41L encodes a chemokine binding protein which binds and inhibits CCL21 \[[@CR54]\] and deletion mutants lacking the A41L gene, induce stronger virus-specific CD8+ T-cell responses \[[@CR54], [@CR55]\]. LSDV does not have a homolog of the A41L gene; there must be other mechanisms that mammalian poxviruses have evolved to evade the effects of CCL21, which is clearly important for the host in clearing poxvirus infection. In selecting/designing a vaccine vector it would be desirable to use a virus which lacks A41L and does not down regulate CCL21 if a strong CD8+ T cell response is required.

Interestingly, MVA, LSDV, FWPV and CNPV all down-regulated the gene encoding the murine homolog for DC-specific ICAM-3--grabbing nonintegrin (DC SIGN) (Cd209a). Furthermore MVA, LSDV and FWPV down-regulated an additional DC SIGN homolog, CD209b (SIGNR1) (Table [3](#Tab3){ref-type="table"}).

LSDV has a host-range restricted to ruminants and is currently being investigated as an HIV vaccine vector \[[@CR3], [@CR56]\]. LSDV caused the most significant response in mice compared to the other poxviruses, both in terms of the number of up-regulated genes and the magnitude and breadth of the type I Interferon response (Fig. [4](#Fig4){ref-type="fig"}). LSDV clustered independently from the avipoxviruses and MVA. LSDV up-regulated genes are involved in the antigen processing and presentation pathway (H2-T24, Tap1 and Tap2). Furthermore, LSDV uniquely up-regulated the gene encoding macrophage migration inhibitory factor (Mif), which is important in both macrophage function and T-cell immunity \[[@CR57]\], and Ddx58, otherwise known as RIG-I (retinoic acid-inducible gene 1), which recognises viral RNA, activating downstream signalling pathways that facilitate type I IFN production \[[@CR58]\]. The up-regulation of RIG-I may, in part, be responsible for the increased type I IFN response seen in LSDV-infected mice. Another one of the many genes uniquely up-regulated by LSDV was the transcription factor (Myc) that promotes growth, proliferation and apoptosis \[[@CR59]\]. Myc has been shown to be up-regulated in response to infection with NYVAC and MVA in HeLa cells \[[@CR13]\]. The absence of Myc up regulation in mouse spleens by MVA was unexpected. In a study done in Rhesus macaques rLSDV vector expressing an HIV polyprotein was immunogenic at a dose 1000-fold lower than that of rMVA. Both CD4+ and CD8+ responses were induced, rather than a predominance of CD4+ T cells observed typically for poxvirus vectors \[[@CR3]\].

Both LSDV and MVA up-regulated a cellular homolog of Moloney Leukemia Virus 10 (Mov10), which has been shown to inhibit retrovirus replication and infectivity \[[@CR60]\]. It specifically interacts with the nucleocapsid domain of HIV Gag \[[@CR60]\], which may have implications for vaccine vectors encoding Gag proteins. Avipoxviruses may therefore be better vectors than MVA or LSDV for the expression of Gag.

CNPV and FWPV induce the up regulation of two immunoglobulin genes (Ighg and Ighg3 (IgG3)) with CNPV up regulating a third, Ighm (Fig. [4b](#Fig4){ref-type="fig"}). All six viruses down-regulated the IgE FC receptor alpha (Fcer2a) polypeptide gene. IgE is involved in allergic responses and not vaccine responses. Antibodies of the same epitope specificity but of a different subclass can have different antibody effector functions \[[@CR61]\]. In a recent comparison of the immune responses resulting from the partially effective clinical RV144 HIV-1 trial and the ineffective VAX003 trial, it was shown that HIV-1--specific IgG3 antibodies were correlated with decreased risk of HIV-1 infection in the RV144 trial. It is suggested that the canarypox virus, ALVAC-HIV (vCP1521) prime component of RV144 may have stimulated different antibody subclasses, specifically IgG3, compared to the protein-only vaccine (VAX003) \[[@CR61]\]. The up regulation of IgG3 specifically by FWPV and CNPV in vivo, suggests that these two avipoxvirus vectors may be involved in stimulation of the clinically important IgG3 antibody subclass. Up regulation of IgG3 was not detected in ALVAC-infected monocyte derived dendritic cells (MDDCs) \[[@CR15]\]; this potentially significant finding is an example of the importance of in vivo testing.

Type I IFN responses have been highlighted in previous studies investigating host gene expression changes in response to different host-restricted poxviruses \[[@CR14], [@CR15]\]. Type I IFN induces an extensive range of interferon stimulated genes (ISGs) with various anti-viral functions (reviewed here: \[[@CR62]\]). In concurrence with previous studies of poxvirus-induced host responses \[[@CR14], [@CR15]\], Type I IFN responses were initiated by MVA, LSDV, CNPV and FWPV, with LSDV inducing the strongest response in mice (Fig. [4](#Fig4){ref-type="fig"}), followed by CNPV and FWPV, with MVA inducing a relatively low IFN response. FeP2 and PEPV induced very little ISG expression. The observed enhanced type I IFN-specific and other immune responses elicited by LSDV, FWPV and CNPV compared to MVA may be due to the absence of virus-encoded immunomodulators in these viruses which could still be present in MVA. Our results suggest that LSDV may be more immunogenic than FWPV and CNPV in mice. It is not known whether this greater IFN-response induced by LSDV in comparison to avipoxviruses would lead to enhanced clearance of the virus and a decreased immune response to any potential transgenes, or whether the increased IFN response would result in an improved immune response to the transgene, should LSDV be used as a vaccine vector.

Toll-like receptors are important regulators of the innate immune system. Poxviruses are recognized by a number of different pathogen recognition receptors (PRRs) with innate immune sensing patterns differing considerably between species and even between different derivatives of the same parent species (VACV, MVA and NYVAC) \[[@CR23]\]. In our study we show that TLR13, TLR3 and TLR8 are up-regulated by four poxviruses analysed (CNPV, FWPV, MVA and LSDV). In addition, TLR7 is up-regulated by CNPV, MVA and LSDV but not by FWPV (Table [2](#Tab2){ref-type="table"}). Up regulation of TLR 3, which detects double stranded RNA, has been observed in response to MVA, but not NYVAC infection of MDDCs \[[@CR14]\]. IFNs have been shown to up regulate TLR gene expression in viral infections \[[@CR63]\]. Here we have established that CNPV, FWPV, MVA and LSDV all induce significant type I IFN responses and we suggest that the up regulation of TLR expression may be a result of this.

MVA, FWPV and CNPV all up regulate the protease Caspase 1 (Casp1) whereas LSDV does not (Fig. [4](#Fig4){ref-type="fig"}). Casp1 dependent programmed cell death (pyroptosis), unlike apoptosis, is a pro-inflammatory process that has recently been recognised as important for the control of microbial infections \[[@CR64]\]. All of MVA, FWPV, CNPV and LSDV also significantly up-regulated caspase 4 (casp 4) (historically called caspase 11 in the mouse) (gene lists reference) which is required for the maturation of the pro-proteins of IL-1b and IL-18 (proIL-1b, proIL-18) and plays an important role in the activation of caspase-1 in inflammasome complexes, and therefore inflammation \[[@CR65]\]. The correlation of caspase up-regulation with either apoptosis or pyroptosis is still to be assessed.

Application of the systems biology approach to vaccines and determination of innate immune signatures has proven useful in predicting the immunogenicity of the highly effective yellow fever vaccine (YF-17D) \[[@CR20]\], the seasonal influenza vaccines \[[@CR21]\] and the immunogenic but inefficacious Merck Ad5/HIV vaccine \[[@CR22]\]. Several of the innate immune signatures observed in tested vaccines, were common to one or more of the poxviruses investigated here. The gene encoding monocyte chemotactic protein 1 (MCP1) (Ccl2) was up-regulated by 5 out of the 6 poxviruses (MVA, LSDV,CNPV,FWPV and PEPV). This gene was positively correlated with the CD8+ T cell response to Merck Ad5/HIV vaccination \[[@CR22]\]. Immunoglobulin genes, Ighm (up-regulated by CNPV) and IgK (down-regulated by LSDV) were positively correlated with the antibody response to TIV influenza vaccination \[[@CR21]\]. This suggests that the different poxviruses could be associated with different levels of antibody induction during the adaptive immune response. Based on our data we speculate that LSDV may be more suitable for a T-cell based vaccine and CNPV more suitable for the induction of an antibody response. This reflects the published data on LSDV \[[@CR3]\] and CNPV \[[@CR61]\].

Microarray analyses can provide important information regarding the effect of different clinically relevant viruses on host gene expression. One limitation of microarray data analysis is that as of yet there are no standardised methods of statistical analysis. It has been demonstrated previously that fold change designations and *p*-value cutoffs can significantly alter microarray interpretation \[[@CR66]\]. Here we have chosen stringent fold change and *p*-value cutoffs (log~2~FC ±1, adjusted *p*-value \< 0.05) in line with similar studies \[[@CR11]−[@CR14]\], in order to avoid false discovery and inaccurate biological inferences. We concede that in doing so, some smaller changes in gene expression may have been overlooked. Further work should entail investigating gene dysregulation at different times post infection. Also, innate immune signatures should be directly correlated with subsequent adaptive responses. Correlation of gene expression data with biological or clinical findings would be most informative.

Conclusions {#Sec13}
===========

The findings presented here indicate that six, genetically diverse host-restricted poxviruses, CNPV, FWPV, FeP2, PEPV, MVA and LSDV, produce qualitatively and quantitatively distinct host responses in an in vivo mouse model. These results confirm that transcriptome analysis in a mouse model can be used to determine if poxvirus vectors differ from each other, laying the ground work for further investigation.

Materials and methods {#Sec14}
=====================

Animal ethics approval {#Sec15}
----------------------

The growth of poxviruses in embyonated eggs and the mouse experiments described below were approved by the Animal Research Ethics Committee in the Faculty of Health Sciences, University of Cape Town. The approval numbers are 013/016 and 013/017 respectively.

Viruses {#Sec16}
-------

MVA and wild-type CNPV were obtained from Prof. K. Dumbell's collection at the University of Cape Town and were originally from Prof. A. Mayr (Germany). The fowlpox virus vaccine, DCEP 25 modified strain, was purchased from Merial (Country) and LSDV vaccine, Herbivac® (Ceva), was kindly donated by Deltamune (Pretoria, South Africa). FeP2 was from a Feral Pigeon (*Columba livia*) \[[@CR26], [@CR27]\] and PEPV from an African penguin (*Spheniscus demersus*) \[[@CR27], [@CR29]\]. Virus isolates were grown and titrated on the chorioallantoic membranes (CAMs) of embryonated 10--11 day old (MVA, CNPV, FWPV) or 7 day old (LSDV) Specific pathogen--free (SPF) White Leghorn chicken eggs, which were obtained from Avifarms (Pty) Ltd (Lyttelton, South Africa), using a method described previously \[[@CR26]\]. Titrations were performed on CAMs for avipoxviruses and MVA and on Madin Darby bovine kidney (MDBK) cells for LSDV.

Virus infection of mice {#Sec17}
-----------------------

Seven week old naive female BALB/c mice were randomly divided into groups of three and each mouse was inoculated intravenously (i.v) with 10^5^ pfu/100 ul poxvirus, diluted in PBS or mock infected with PBS alone or egg extract (100 μl). The egg extract was made from uninfected CAMs, following the same extraction and purification procedure as the virus samples above. We compared the gene expression profiles of the groups of mice that were mock-infected with egg extract and PBS. No difference in gene expression was observed between the control samples. For each different virus, three groups of three mice each were inoculated. At 24 h post infection, the mice were sacrificed by cervical dislocation without anaesthesia and the spleens were harvested and placed in RNAlater (Qiagen, Venlo, Limburg, NL).

RNA extraction {#Sec18}
--------------

Mouse spleens were removed from RNAlater and the three spleens in each group were pooled and homogenized thoroughly using a TissueRuptor (Qiagen) in TRIzol® reagent (Life Technologies, Carlsbad, CA, USA). Total RNA was isolated using TRIzol® Plus RNA Purification Kit (Life Technologies, Carlsbad, CA, USA) with On-column PureLink® DNase treatment according to manufacturer's instructions. RNA was resuspended in RNase free water and quality checked using the Nanodrop ND1000 (Thermoscientific, Waltham, MA, USA) and the Agilent Bioanalyzer Nano Assay (Agilent, Santa Clara, CA, USA).

Microarray and data analysis {#Sec19}
----------------------------

mRNA hybridization was performed by IMGM Laboratories GmbH (Martinsried, DE) with the Affymetrix GeneChip Mouse Gene 2.0 ST array (Affymetrix, Santa Clara, CA, USA). Data analysis was performed in R \[[@CR67]\], using packages from the Bioconductor suite (<http://www.bioconductor.org>), and CRAN (<http://cran.rproject.org>). All R code is available in Additional file [1](#MOESM1){ref-type="media"}. Probe level data from. CEL files was normalised using the Robust Multi-array Averaging (RMA) method \[[@CR68]\] obtained as part of the "affy" package \[[@CR69]\] from Bioconductor, resulting in log~2~ transformed values. Boxplots, scatterplots and histogram outputs of the normalised data were obtained and checked for consistency (not shown). Data was annotated using the Mouse Gene ST 2.0 annotation data package from Bioconductor. Non-specific filtering was performed using the Genefilter package \[[@CR70], [@CR71]\]. This step included an intensity filter which filtered the data set such that the intensity of each gene should be \> log2 (100) in at least 20 % of the samples. Secondly, a variance filter was applied such that the interquartile range of log2-intensities should be at least 0.5.

Differential gene expression was determined using a linear model approach using the R package, Limma \[[@CR34]\]. A heatmap was made using heatmap.2 from the CRAN package gplots \[[@CR72]\], and depicted the unsupervised hierarchical clustering based on the genes with *p*-value \< 0.05 and log~2~FC above or below cutoff (±1). Venn diagrams were made using Venny \[[@CR73]\] available at <http://bioinfogp.cnb.csic.es/tools/venny/index.html>. Functional analysis was performed using Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7 web-based tools (<http://david.abcc.ncifcrf.gov/tools.jsp>). Quantitative real time PCR was done on selected mouse genes. GAPDH, HPRT and CD51 were selected as housekeeping genes; IRF7 and Zbp1 were selected as genes which were moderately upregulated by LSDV, MVA and avipoxviruses CNPV and FWPV; and IGFbp3 was selected as a gene which was downregulated by LSDV.

Additional file {#Sec20}
===============

Additional file 1:**R code used. Supplementary file 2.** Full list of up regulated genes in mouse spleens in response to modified vaccinia Ankara (MVA), lumpy skin disease virus (LSDV), canarypox virus (CNPV), fowlpox virus (FWPV), penguinpox virus (PEPV) and pigeonpox (FeP2). **Supplementary file 3.** Full list of down regulated genes in mouse spleens in response to modified vaccinia Ankara (MVA), lumpy skin disease virus (LSDV), canarypox virus (CNPV), fowlpox virus (FWPV), pigeonpox (FeP2) and penguinpox virus (PEPV).
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